The Food and Drug Administration (FDA) has issued an Emergency Use Authorized for the unapproved drug Peramivir, administered intravenously to treat 2009 H1N1 Influenza. Peramivir is a neuraminidase inhibitor that is still in Phase 3 clinical trials. Peramivir is authorized for patients admitted to the hospital under the care of a clinician skilled in the diagnosis and management of patients with potentially life threatening illness and the ability to recognize and manage medication related adverse events. Peramivir is specifically authorized for the treatment of adult and pediatric patients when IV therapy is appropriate, and the patient is not responding to either oral or inhaled antiviral therapy drug delivery by a route other than intravenous and the clinician judges intravenous therapy for 2009 H1N1 Influenza is appropriate due to other circumstances. Peramivir is not authorized for the treatment of seasonal influenza A or B virus infection, for outpatients with acute uncomplicated 2009 H1N1 Influenza virus infection or for pre or post exposure chemoprophylaxis of influenza.
For additional information and to request Peramivir under the Emergency Use Authorization: http://www.cdc.gov/h1n1flu/eua/peramivir.htm
You are receiving this email because you are a registered member of the Delaware Health Alert Network.
If you are not a member and would like to subscribe, please complete the form found online at: http://dhss.delaware.gov/main/mailforms/dph_hanform.aspx.